These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 455314)

  • 1. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
    Strong JM; Kinney YE; Branfman AR; Cysyk RL
    Cancer Treat Rep; 1979 May; 63(5):775-80. PubMed ID: 455314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
    Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
    J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
    Roboz J; Suzuki R; Rose E
    J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
    Lankelma J; Penders PG; Leyva A; Pinedo HM
    Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
    Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
    Erlichman C; Strong JM; Chabner BA
    Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas chromatography and mass spectrometry of N-(phosphonacetyl)-L-aspartic acid.
    Branfman AR; Valia KH; Bruni RJ
    J Chromatogr; 1978 Apr; 151(1):71-4. PubMed ID: 641126
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
    Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
    Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
    Kensler TW; Jayaram HN; Cooney DA
    J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. II. Studies on its mechanism and reversibility.
    Sieber SM; Botkin CC; Leslie KA; Cooney DA
    Teratology; 1980 Dec; 22(3):321-8. PubMed ID: 7233337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of tiamenidine hydrochloride in human serum using gas chromatography mass spectrometry.
    Fehlhaber HW; Metternich K; Tripier D; Uihlein M
    Biomed Mass Spectrom; 1978 Mar; 5(3):188-91. PubMed ID: 630059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gas chromatographic determination of verapamil in plasma and urine.
    Hege HG
    Arzneimittelforschung; 1979; 29(11):1681-4. PubMed ID: 543874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple method for the quantitative analysis of endogenous folate catabolites p-aminobenzoylglutamate (pABG) and its acetamido (apABG) derivative in human serum and urine by liquid chromatography-tandem mass spectrometry.
    Sokoro AA; Etter ML; Lepage J; Weist B; Eichhorst J; Lehotay DC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):9-16. PubMed ID: 16427369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the antidepressant levoprotiline and its N-desmethyl metabolite in biological fluids by gas chromatography/mass spectrometry.
    Ackermann R; Kaiser G; Schueller F; Dieterle W
    Biol Mass Spectrom; 1991 Nov; 20(11):709-16. PubMed ID: 1799582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.